Published in J Natl Cancer Inst on March 10, 2010
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08
Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano (2012) 1.03
Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany. Health Econ Rev (2014) 0.99
Stereotactic radiation therapy for liver metastases: factors affecting local control and survival. Radiat Oncol (2015) 0.99
Combination drug delivery approaches in metastatic breast cancer. J Drug Deliv (2012) 0.97
Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. Ann Surg (2016) 0.96
Cancer drugs should add months, not weeks, say experts. Nat Med (2011) 0.95
A new emergency in oncology: Bone metastases in breast cancer patients (Review). Oncol Lett (2013) 0.95
Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells. Cancers (Basel) (2013) 0.94
Pulmonary metastasis from breast cancer with an 18-year disease-free interval: implication of the role of surgery. Int Surg (2013) 0.94
Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist (2013) 0.94
Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis. J Cancer Res Clin Oncol (2011) 0.92
Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care (Basel) (2014) 0.91
Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Trans A Math Phys Eng Sci (2012) 0.90
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol (2013) 0.87
Apoptosis signal-regulating kinase 1 is associated with the effect of claudin-6 in breast cancer. Diagn Pathol (2012) 0.86
The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford) (2016) 0.84
Nucleostemin expression in invasive breast cancer. BMC Cancer (2014) 0.84
A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens. Int J Nanomedicine (2011) 0.84
Radiotherapy in patients with distant metastatic breast cancer. Radiat Oncol (2014) 0.83
The long non-coding RNA EPB41L4A-AS2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors. Oncotarget (2016) 0.83
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res (2014) 0.82
Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg (2013) 0.82
Sequential Metastatic Breast Cancer Chemotherapy: Should the Median be the Message? Front Public Health (2013) 0.82
Can oncology recapitulate paleontology? Lessons from species extinctions. Nat Rev Clin Oncol (2015) 0.82
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy. Curr Oncol (2012) 0.81
Oligometastatic breast cancer: A mini review. Indian J Med Paediatr Oncol (2014) 0.79
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential. Cancer Biol Ther (2015) 0.79
Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae. Breast J (2013) 0.79
Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase. Br J Cancer (2015) 0.78
Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J (2015) 0.78
Resection of the primary tumor in stage IV breast cancer. World J Clin Oncol (2014) 0.78
Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis (2016) 0.77
Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Res (2015) 0.77
Treatment strategy for metastatic breast cancer according to intrinsic subtype. Int J Clin Oncol (2010) 0.77
Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells. Indian J Pharm Sci (2012) 0.77
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. J Exp Clin Cancer Res (2013) 0.76
Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009. Clin Epidemiol (2011) 0.76
Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer (2015) 0.75
Diagnostic dilemma involving a mass in the parapharyngeal space: A metastatic breast carcinoma masquerading as a malignant salivary gland tumor. Indian J Nucl Med (2015) 0.75
Current operative management of breast cancer: an age of smaller resections and bigger cures. Int J Breast Cancer (2011) 0.75
A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer (2014) 0.75
Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission. Curr Oncol (2016) 0.75
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer (2015) 0.75
Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient? Cureus (2015) 0.75
Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
Induction of the MCP chemokine cluster cascade in the periphery by cancer cell-derived CCL3. Cancer Lett (2016) 0.75
Pituitary metastasis from breast cancer presenting as diabetes insipidus. BMJ Case Rep (2014) 0.75
An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation. Cancers (Basel) (2011) 0.75
Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization. EJNMMI Res (2016) 0.75
Intraoperative Identification of Liver Cancer Microfoci Using a Targeted Near-Infrared Fluorescent Probe for Imaging-Guided Surgery. Sci Rep (2016) 0.75
Making the Case: Intra-arterial Therapy for Less Common Metastases. Semin Intervent Radiol (2017) 0.75
The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep Pract Oncol Radiother (2016) 0.75
Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. Semin Intervent Radiol (2017) 0.75
Melatonin-induced KiSS1 expression inhibits triple-negative breast cancer cell invasiveness. Oncol Lett (2017) 0.75
Radiosurgery for liver metastases. A single institution experience. Rep Pract Oncol Radiother (2016) 0.75
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 11.73
Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol (2004) 4.51
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol (2006) 3.77
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer (2007) 2.84
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Is breast cancer survival improving? Cancer (2004) 2.73
Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg (2006) 2.49
Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol (2007) 2.36
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Extending survival with chemotherapy in metastatic breast cancer. Oncologist (2005) 2.17
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg (2008) 2.14
Does aggressive local therapy improve survival in metastatic breast cancer? Surgery (2002) 2.13
The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol (2005) 2.13
Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol (2002) 2.10
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol (2005) 2.05
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg (2003) 1.71
Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol (2008) 1.71
Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol (2007) 1.66
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant (2006) 1.66
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol (2008) 1.59
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer (2005) 1.48
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol (2002) 1.46
Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol (2004) 1.45
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42
Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother (2005) 1.40
Liver metastases from breast cancer: long-term survival after curative resection. Surgery (2000) 1.38
The role of surgery in the management of solitary pulmonary nodule in breast cancer patients. Eur J Surg Oncol (2007) 1.35
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol (2008) 1.25
Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg (2002) 1.23
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer (1999) 1.19
Effects of anaesthesia and surgery on the immune response. Acta Anaesthesiol Scand (1992) 1.18
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer (2001) 1.17
The role of surgery in treatment of stage IV melanoma. J Surg Oncol (2006) 1.17
Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care (2008) 1.16
A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer (2005) 1.15
Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol (2000) 1.12
Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients. World J Surg (2005) 1.08
Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol (2008) 1.07
Surgical treatment of hepatic metastases from breast cancer. Breast Cancer Res Treat (2000) 1.06
A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist (2003) 1.06
Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol (2003) 1.05
Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol (1995) 1.05
[Hepatic resection for breast cancer metastases: results and prognosis (65 cases)]. Ann Chir (2001) 1.04
Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol (2007) 1.02
The solitary pulmonary nodule in the patient with breast cancer. Surgery (1984) 1.01
Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer (2004) 1.00
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.99
CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol (2008) 0.98
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol (2005) 0.98
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy. Oncologist (2006) 0.96
Long-term survival after resection of pulmonary metastases from carcinoma of the breast. Ann Thorac Surg (1992) 0.94
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J (2002) 0.93
Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA (1979) 0.93
Disease-free survival after resection of lung metastases in patients with breast cancer. Eur J Surg Oncol (2003) 0.93
Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant (2006) 0.91
Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol (2007) 0.91
The oligometastatic state in breast cancer: hypothesis or reality. Breast (2005) 0.91
Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg (2005) 0.90
Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol (2006) 0.90
Pulmonary resection for metastatic breast cancer. Ann Thorac Surg (1994) 0.90
Liver metastases of breast cancer: results of liver resection. Anticancer Res (1998) 0.89
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol (2006) 0.89
Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant (2007) 0.89
High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev (2005) 0.88
Metastasectomy as a cytoreductive strategy for treatment of isolated pulmonary and hepatic metastases from breast cancer. Surg Oncol (1999) 0.87
Pulmonary resection in metastatic carcinoma. Chest (1978) 0.85
Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast (2007) 0.85
The significance of prognostic factors for the resection of pulmonary metastases of breast cancer. Thorac Cardiovasc Surg (1994) 0.85
Pulmonary resection for metastatic breast cancer. Arch Surg (1992) 0.85
Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer (1996) 0.85
[Complete resection of isolated lung metastasis from breast carcinoma results in a strong increase in survival]. Minerva Chir (2000) 0.83
Does resection of an intact breast primary improve survival in metastatic breast cancer? Oncology (Williston Park) (2007) 0.83
Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer (2007) 0.82
Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol (1979) 0.81
Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol (1984) 0.81
Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg (2008) 0.81
The contribution of surgery to the management of carcinomatous pulmonary metastases. Cancer (1978) 0.80
[Surgical excision of pulmonary metastasis of cancer of the breast: apropos of 40 patients]. Bull Cancer (1998) 0.80
Percutaneous hepatic arterial infusion of cisplatin for metastatic breast cancer. Cancer Treat Rep (1987) 0.79
Surgery for pulmonary metastases. Who are the 10-year survivors? Cancer (1994) 0.79
Surgery for pulmonary metastases. Surg Clin North Am (1980) 0.79
[Hepatic resection for breast cancer metastasis. The concept of adjuvant surgery]. Bull Cancer (1997) 0.78
Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol (1988) 0.78
Surgery for palliation and treatment of advanced breast cancer. Surg Oncol (2007) 0.77
Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer. Anticancer Res (2006) 0.77
Breast surgery in advanced breast cancer: local control in the presence of metastases. Breast (2007) 0.77
Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Breast J (2007) 0.77
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res (1999) 0.76
Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer. Eur J Cancer (1997) 0.76
Continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy for metastatic breast cancer. Cancer Treat Rep (1987) 0.76
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol (2007) 7.45
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA (2006) 6.45
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
CNS metastases in breast cancer. J Clin Oncol (2004) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Informing clinical trial participants about study results. JAMA (2002) 3.76
Local therapy and survival in breast cancer. N Engl J Med (2007) 3.33
Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res (2008) 3.25
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst (2008) 3.16
Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst (2003) 3.16
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol (2006) 3.15
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2008) 3.08
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol (2008) 3.04
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol (2009) 2.98
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer (2008) 2.82
Brain metastases: the HER2 paradigm. Clin Cancer Res (2007) 2.81
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res (2004) 2.77
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol (2005) 2.70
The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer (2010) 2.63
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol (2010) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) (2012) 2.50
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol (2006) 2.48
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol (2013) 2.35
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst (2003) 2.33
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol (2011) 2.30
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol (2006) 2.24
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw (2006) 2.15
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol (2008) 2.10
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res (2007) 2.02
Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys (2007) 2.02
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation (2005) 2.01
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat (2010) 1.97
Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst (2007) 1.97
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 1.96
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast (2013) 1.94
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res (2007) 1.88
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol (2011) 1.85
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis. Breast Cancer Res Treat (2007) 1.82
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer (2011) 1.79
Surveillance testing among survivors of early-stage breast cancer. J Clin Oncol (2007) 1.77
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med (2015) 1.76
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol (2005) 1.71